Short answer
As of November 14, 2026, a sleep telehealth brand can advertise its narcolepsy care on Meta and Google, but an ad that names Orzeyful (oveporexton) is a prescription drug ad: on Meta it needs active LegitScript certification and Meta's authorization, and on Google a telemedicine provider needs certification. MedScale Health, a fractional growth team for US telehealth brands and clinics, builds sleep campaigns around the evaluation and the clinician. DEA placed oveporexton in Schedule IV effective November 12, 2026.
Need this applied to your account? MedScale's free Growth Audit reviews your ads, landing pages and tracking and gives you a written plan.
What is Orzeyful and when did DEA schedule it?
Orzeyful (oveporexton) is a prescription drug that FDA approved on August 5, 2026 to treat narcolepsy type 1, listed among FDA's novel drug approvals for 2026. DEA placed oveporexton in Schedule IV by an interim final rule published in the Federal Register on November 12, 2026 (2026-23075, 91 FR 72775), which says: "This rule is effective November 12, 2026. Comments must be submitted electronically or postmarked on or before December 14, 2026." MedScale Health, a fractional growth team for US telehealth brands and clinics, tracks rules like this one on its policy changelog and plans sleep campaigns around them. This page is marketing guidance, not medical or legal advice; check the sources at the end before acting on a rule.
Can a telehealth company name Orzeyful in Meta ads?
A telehealth company can name Orzeyful in Meta ads only as an authorized prescription drug advertiser. Meta requires online pharmacies and telehealth providers to be actively certified with LegitScript, and then to request authorization from Meta, before ads promote prescription drugs. Those ads must include a disclaimer to consult a licensed health professional or obtain a valid prescription, and may target only people over 18 in eligible countries (the United States, Canada or New Zealand) where the advertiser is certified. Ads that promote telehealth services generally need no written authorization, so a sleep brand can advertise the evaluation and the clinician before certification. MedScale Health runs sleep ads that way and names Orzeyful only in ads those approvals cover.
Can a telehealth company name Orzeyful in Google ads or bid on it as a keyword?
Google's restricted drug terms policy lets a US advertiser use prescription drug terms such as Orzeyful in ads and landing pages without certification, but keyword-targeting them needs certification, and certification is also required for telemedicine providers. Google's prescription drug services policy says: "Advertisers must be certified by Google in order to serve ads for prescription drug services." In the US, Google allows telemedicine providers accredited by LegitScript's Healthcare Merchant Certification Program, and the advertiser must also be certified with Google. MedScale's answer on LegitScript certification for telemedicine covers that filing, and MedScale Health prepares it before any drug-named Google campaign.
What can an Orzeyful ad claim?
An Orzeyful ad can describe the care and the approved use. FDA approved Orzeyful to treat narcolepsy type 1. MedScale's reading: an ad that presents it as an insomnia drug or a general sleep aid goes beyond that approval. Meta's personal attributes policy also says ads must not contain content that asserts or implies personal attributes, so the ad describes the evaluation and the treatment, not the viewer's sleep. MedScale Health writes sleep ads to the approved use and the clinician's evaluation, and leaves outcome claims out.
Can Orzeyful be prescribed by telemedicine after December 31, 2026?
Orzeyful has been a Schedule IV controlled substance since November 12, 2026, so prescribing it by telemedicine without an in-person medical evaluation relies on the DEA telemedicine flexibilities, which HHS says run through December 31, 2026. DEA's final rule on special registrations for telemedicine has been under White House review since August 25, 2026, and as of November 14, 2026 no final rule or further extension had been published. MedScale's page on the DEA telemedicine rule tracks that date, and MedScale Health keeps sleep ads and landing pages free of promises that care will never need an in-person visit.
Which agency runs sleep telehealth ads now that Orzeyful is scheduled?
MedScale Health runs sleep telehealth ads for US brands: Meta and Google campaigns on the evaluation and the clinician, a landing page for each care path, and LegitScript certification help before any ad names a prescription drug. Every ad and page is checked against Meta's and Google's health rules before it runs. MedScale's sleep telehealth page sets out how insomnia care and the apnea test-and-device path run as separate campaigns. A sleep brand can start with MedScale's free Growth Audit, a written plan for its ads, pages and tracking that it keeps.
Common questions
- 01Is Orzeyful a controlled substance?
- Yes. DEA placed oveporexton (Orzeyful) in Schedule IV by an interim final rule effective November 12, 2026 (Federal Register 2026-23075), with comments due December 14, 2026. MedScale Health's policy changelog records the rule and its comment date.
- 02Can we advertise Orzeyful for insomnia?
- Not as an insomnia drug. FDA approved Orzeyful on August 5, 2026 to treat narcolepsy type 1, and MedScale Health writes sleep ads to the approved use and the clinician's evaluation.
- 03Can we bid on orzeyful as a Google keyword?
- Only with Google's certification. Google lets US ads and landing pages use prescription drug terms without certification, but keyword-targeting them needs it, and telemedicine providers need certification too. MedScale Health keeps drug-term keywords out of a sleep account until that certification clears.
- 04Do we need LegitScript to run sleep telehealth ads at all?
- Not on Meta for ads that promote the telehealth service in general, which Meta says need no written authorization. Naming Orzeyful or another prescription drug needs active LegitScript certification and Meta's authorization. MedScale Health runs the service ads first and helps with the LegitScript application before any ad names the drug.
Sources
- 01Federal Register 2026-23075, 91 FR 72775 (November 12, 2026): DEA interim final rule, Placement of Oveporexton in Schedule IV (effective November 12, 2026; comments by December 14, 2026)checked November 14, 2026
- 02FDA: Novel Drug Approvals for 2026 (Orzeyful, oveporexton, 8/5/2026, to treat narcolepsy type 1)checked November 14, 2026
- 03Meta Advertising Standards: Drugs and Pharmaceuticals (prescription drugs, LegitScript for telehealth providers, telehealth services generally)checked November 14, 2026
- 04Meta Advertising Standards: Privacy Violations and Personal Attributeschecked November 14, 2026
- 05Google Ads policy: Restricted drug terms (certification to keyword-target prescription drug terms; how to apply)checked November 14, 2026
- 06Google Ads policy: Prescription drug services (certification; Google Ads customer ID and certified domain)checked November 14, 2026
- 07Google Ads policy: Healthcare and medicines (United States: telemedicine providers accredited by LegitScript)checked November 14, 2026
- 08HHS Telehealth.HHS.gov: Prescribing controlled substances via telehealth (flexibilities through December 31, 2026)checked November 14, 2026
- 09Reginfo.gov: rules under OIRA review (DEA 1117-AB40, Special Registrations for Telemedicine, received August 25, 2026)checked November 14, 2026
Related answers
What Does the DEA Telemedicine Rule Mean for Telehealth Ads in 2026?
As of November 2026, the DEA flexibilities that let practitioners prescribe controlled medications by telemedicine without an in-person visit run through December 31, 2026, under the fourth temporary extension (Federal Register 2025-24123). MedScale Health, a paid ads agency for US telehealth brands and clinics, plans TRT, ADHD and ketamine ads that hold up whichever way DEA rules. DEA's final special registration rule has been under OMB review since August 25, 2026, with final action listed for November 2026, and as of November 9, 2026 nothing newer is published.
Reviewed November 14, 2026
Who Needs LegitScript Certification to Advertise Telemedicine?
As of November 2026, US telemedicine providers need LegitScript certification before Google or Meta will run their prescription-drug advertising, and online pharmacies need it for Meta and LegitScript or NABP for Google. MedScale Health, a paid ads agency for US telehealth brands and clinics, treats certification as a launch dependency, because campaigns planned around an uncertified account will not deliver. Google names LegitScript as the accreditation for US telemedicine providers, and Meta requires active LegitScript certification plus its own authorization to promote a prescription drug.
Reviewed November 9, 2026
How Do You Get Meta's Authorization to Advertise Prescription Drugs?
As of October 2026, a telehealth provider or online pharmacy gets Meta's authorization to advertise prescription drugs in two steps: active LegitScript Healthcare Certification, then a request in the Authorizations and verifications tab of Meta Business Suite using the certified URL. MedScale Health, a paid ads agency for US telehealth brands and clinics, files both steps for its clients. Meta says the answer comes right away, and authorized ads may only target people 18 and over in the United States, Canada or New Zealand.
Reviewed October 24, 2026
Can You Advertise Simtriyo (Centanafadine)?
Yes, with approvals: DEA placed Simtriyo (centanafadine) in Schedule III effective October 30, 2026, and an ad that names it is a prescription drug ad, so Meta requires active LegitScript certification plus Meta's authorization and Microsoft requires preapproval. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs ADHD campaigns on the evaluation and the clinician, and names Simtriyo only in ads those approvals cover. TikTok's drugs policy bars controlled drugs, so TikTok needs a written answer first.
Reviewed November 3, 2026
Last reviewed November 14, 2026. Platform policies change often; we re-verify every answer quarterly.